Riskpilot← Back to searchSign inGet full accessBIOSENTRUM AS
ASActiveOrg 979174330Prof. Olav Hanssens V. 15, 4021 StavangerResearch and experimental development on natural sciences and engineering · NACE 7210Est. 19970 employeeswww.biosentrum.no
Revenue 2024
NOK 2,2M
EBITDA margin
94.1%
+742% vs 2023
Equity ratio
-203.9%
Financial strength
Net profit 2024
NOK 1,9M
+525% vs 2023
| Revenue | NOK 2,2M | — |
| EBITDA | NOK 2,1M | +742% |
| Net profit | NOK 1,9M | +525% |
| Total assets | NOK 367K | -44% |
| Equity | NOK -748K | +72% |
| Employees | 0 | — |
Legal name
BIOSENTRUM AS
Org number
979174330
Legal form
Aksjeselskap
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
6. august 1997
Share capital
NOK 100 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Address
Prof. Olav Hanssens V. 15, 4021 Stavanger
Website
www.biosentrum.no
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2 131 | 1 835 | 2 277 | 1 880 | 794 | 1 318 | 2 362 | 5 975 | 2 789 | 0 | 2 200 |
| Staff expenses | −23 | −23 | −11 | −1 127 | −1 372 | −1 545 | −590 | −341 | −277 | −125 | −0 |
| EBITDA | 201 | −430 | 325 | −1 474 | −2 067 | −1 425 | −273 | 926 | −58 | −323 | 2 070 |
| Depreciation & amort. | −19 | −16 | −11 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| EBIT | 183 | −446 | 314 | −1 474 | −2 067 | −1 425 | −273 | 926 | −58 | −323 | 2 070 |
| Net financials | −8 | −10 | −12 | −10 | −16 | −81 | −101 | −44 | −83 | −130 | −142 |
| Profit before tax | 174 | −456 | 302 | −1 484 | −2 082 | −1 506 | −374 | 881 | −141 | −453 | 1 928 |
| Tax | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| Net profit | 174 | −456 | 302 | −1 484 | −2 082 | −1 506 | −374 | 881 | −141 | −453 | 1 928 |
| Item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 1 628 | 11 890 | 5 603 | 6 051 | 367 | 486 | 1 814 | 3 403 | 4 085 | 654 | 367 |
| Equity | 299 | 843 | 1 645 | 1 000 | −1 082 | −2 589 | −2 963 | −2 081 | −2 223 | −2 676 | −748 |
| Long-term debt | 800 | 800 | 800 | 800 | 800 | 2 600 | 2 900 | 2 900 | 2 900 | 2 900 | 1 100 |
| Short-term debt | 529 | 10 247 | 3 158 | 4 251 | 650 | 475 | 1 877 | 2 584 | 3 408 | 429 | 15 |
| Total debt | 1 329 | 11 047 | 3 958 | 5 051 | 1 450 | 3 075 | 4 777 | 5 484 | 6 308 | 3 329 | 1 115 |
EBITDA margin
94.1%
This company
15.8%
Market median
+496% vs market
20142024
Equity ratio
-203.9%
This company
38.2%
Market median
-634% vs market
20142024
Return on equity
192753500.0%
This company
18.4%
Market median
+1047573270% vs market
20142024
Net profit margin
87.6%
This company
8.1%
Market median
+981% vs market
20142024
Asset turnover
6.00×
This company
1.12×
Market median
+436% vs market
20142024
Debt / equity
1.49×
This company
0.62×
Market median
-140% vs market
20142024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Brønnøysundsregistrene · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Brønnøysundsregistrene · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Brønnøysundsregistrene · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via Brønnøysundsregistrene · Period 2014-01-01 – 2014-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
JS Chief Executive Officer | Chief Executive Officer | 2022 | — | — |
AJ Chief Executive Officer | Chief Executive Officer | 2006 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2023 | — | — | |
| Board of Directors | 2023 | — | — | |
| Board of Directors | 2023 | — | — | |
| Board of Directors | 2023 | — | — | |
| Chairman | 2023 | — | — | |
| Chairman | 2015 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Norce Innovation As | Company | 100.0% | 100.0% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Universitetet I BergenNorce Norwegian Research Centre AsNorce Innovation As
BIOSENTRUM AS (this company)Board members of BIOSENTRUM AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Jarle Skeidsvoll | Chief Executive Officer | 0 companies |
| Arild Johannessen | Chief Executive Officer | 0 companies |
| Henrik Solberg-Johansen | Chairman | 0 companies |
| Gunnar Kleppe | Board of Directors | 0 companies |
| Susanne Cajsa Christina Gitlesen | Board of Directors | 0 companies |
| Hans Torstein Kleivdal | Board of Directors | 0 companies |
| Cecilie Nordbø Hvammen | Chairman | 0 companies |
| Torkell Gjerstad | Chairman | 0 companies |